Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE β0-THALASSEMIA

Trial Profile

A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE β0-THALASSEMIA

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Glutamine (Primary)
  • Indications Sickle cell anaemia; Thalassaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Emmaus Medical
  • Most Recent Events

    • 23 Oct 2018 According to an Emmaus medical media release, data will be presented at 12th Annual Sickle Cell Disease and Thalassaemia (ASCAT) Conference.
    • 31 Aug 2018 Biomarkers information updated
    • 19 Jul 2018 Results assessing l-Glutamine in Sickle Cell Disease published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top